CREO

Creo Medical Group PLC

Health Care First-pass screen £54m

320/1000 Overall fit

AI beneficiary 35% 20

Operating leverage 25% 48

Valuation 25% 30

Downside protection 15% 40

First-pass take

Early-stage medtech company with strong revenue growth (50% YoY) and cost discipline, but unprofitable with material going concern risk, no AI exposure, and declining gross margins on higher volumes.

Flags

loss-makingcash-burngoing-concernno-valuation-datacustomer-concentrationnegative-fcfmargin-pressure